Pharmacology, Toxicology and Pharmaceutical Science
Therapeutic Drug Monitoring
100%
Ganciclovir
66%
Posaconazole
66%
Infection
63%
Prospective Study
40%
Molecular Epidemiology
33%
Placebo
33%
Cmin
33%
Mucosa Inflammation
33%
Neutropenia
33%
Inflammation
33%
Human Parainfluenza Virus 3
33%
Anakinra
33%
Antiinfective Agent
33%
Cytomegalovirus
30%
Adverse Event
16%
Melphalan
12%
C Reactive Protein
11%
Sialidase
11%
Antifungal Agent
11%
Immunocompromised Patient
11%
Hemagglutinin
11%
Thymoma
11%
HIV
11%
Multiple Myeloma
9%
Observational Study
9%
Antivirus Agent
8%
Systemic Mycosis
8%
Opportunistic Infection
8%
Randomized Controlled Trial
8%
Haemophilus Influenzae Type B Vaccine
8%
Interleukin 1
6%
Chemotherapy
6%
Therapeutic Window
5%
Mycosis
5%
Medicine and Dentistry
Systematic Review
33%
Antiinfective Agent
33%
Adult Hematology
33%
Therapeutic Drug Monitoring
33%
Molecular Epidemiology
33%
Infection Control
33%
Transplantation
33%
Human Parainfluenza Virus 3
33%
Ganciclovir
33%
Cytomegalovirus
28%
Infection
20%
Adverse Event
13%
Thymoma
11%
Hematology
11%
Hemagglutinin
11%
Sialidase
11%
Heart Graft
11%
Immunocompromised Patient
11%
Infection Prevention
11%
Human Immunodeficiency Virus
11%
Systemic Mycosis
6%
Haemophilus Influenzae Type B Vaccine
6%
Stem Cell Transplant
6%
Antifungal Agent
6%
Drug Dose Reduction
6%
Drug Therapy
6%
Antivirus Agent
6%
Randomized Controlled Trial
6%
Opportunistic Infection
6%
Arm
6%
Keyphrases
Mucositis
33%
Neutropenia
33%
Fever
33%
Therapeutic Drug Monitoring
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Ganciclovir
33%
Randomized Placebo-controlled Trial
33%
Anakinra
33%
Bordetella Bronchiseptica
33%
Bovine Parainfluenza Virus Type 3 (BPIV3)
33%
Cytomegalovirus
22%
High-dose Melphalan
14%
Load Estimation
11%
HIV Patients
11%
Immunocompromised Patients
11%
Viral Load
11%
Heart Transplant Recipients
11%
Thymoma
11%
Multiple Myeloma
11%
Hemagglutinin-neuraminidase Gene
11%
Interleukin-1β
7%
Hematopoietic Stem Cell Transplantation
7%
Liver Function Markers
6%
